Long‐term administration of 3′‐Azido‐2′,3′‐dideoxythymidine to patients with AIDS‐related neurological disease

Robert Yarchoan*, Rose V. Thomas, Jordan Grafman, Alison Wichman, Marinos Dalakas, Nanette McAtee, Gary Berg, Margaret Fischl, Carlo Federico Perno, Raymond W. Klecker, Aby Buchbinder, Steven Tay, Steven M. Larson, Charles E. Myers, Samuel Broder

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

65 Scopus citations


3′‐Azido‐2′,3′‐dideoxythymidine (AZT) has been administered to 7 patients with human immunodeficiency virus associated neurological disease: 3 with dementia, 2 with peripheral neuropathy, 1 with dementia and peripheral neuropathy, and 1 with T‐10 paraplegia. Six of the patients showed improvement in their neurological dysfunction on being administered AZT, as assessed by clinical evaluation, neuropsychological testing, nerve conduction studies, and/or positron emission tomographic scans. Three of these 6 patients showed sustained improvement 5 to 18 months after the initiation of AZT therapy. These results suggest that certain human immunodeficiency virus–associated neurological abnormalities are at least partially reversible following the administration of antiretroviral therapy and provide a rationale for further studies using antiretroviral chemotherapy.

Original languageEnglish (US)
Pages (from-to)S82-S87
JournalAnnals of neurology
Issue number1 S
StatePublished - 1988

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology


Dive into the research topics of 'Long‐term administration of 3′‐Azido‐2′,3′‐dideoxythymidine to patients with AIDS‐related neurological disease'. Together they form a unique fingerprint.

Cite this